





ISSN: 2617-6548

URL: www.ijirss.com



Combating medical corruption: A global review of root causes, consequences, and evidence-based interventions

Anas M. Al Qudah^{1*},  Lara Al-haddad¹,  Alaa A. A. Aljabali²

¹*Faculty of Business, Banking and Finance Department, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan*

²*Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan*

Corresponding author: Anas M. Al Qudah (Email: anas.qudah@yu.edu.jo)

Abstract

Medical corruption poses a widespread and growing threat to healthcare systems globally, with the World Health Organization estimating that 10-25% of global healthcare spending is lost annually to corrupt practices. This systematic review synthesizes existing evidence on the causes, socioeconomic and clinical impacts, and effectiveness of anti-corruption interventions. We critically examine manifestations of corruption, such as bribery, fraudulent billing, kickbacks from pharmaceutical companies, and systemic inequities driven by unethical practices, including informal payments for care. A literature review was conducted across the PubMed, Scopus, and Web of Science databases (2013–2024), screening 1,250 peer-reviewed articles and case studies, with 89 selected. These findings indicate that corruption disproportionately impacts vulnerable groups, leading to medication shortages, unequal access to care, and preventable deaths. Low- and middle-income countries lose 30% of their healthcare funds to corruption, compared to 5-10% in high-income nations. Ongoing barriers to reform include regulatory capture, cultural normalization of bribery, and the lack of whistleblower protections. Emerging technological solutions, such as blockchain for supply chain transparency, AI-driven fraud detection, and crowdsourced corruption-reporting platforms, promise to combat illegal activities. However, anti-corruption interventions must be context-specific, incorporating robust legal frameworks, culturally sensitive ethics training, and international cooperation to address cross-border pharmaceutical fraud. This review uniquely advocates for institutional accountability metrics and the integration of anti-corruption goals into universal health coverage agendas. Policy implications underscore the necessity of political will to dismantle entrenched networks and public-private partnerships to ensure equitable care. Future research should focus on longitudinal studies to assess intervention effectiveness and explore the role of social determinants in exacerbating corruption.

Keywords: Anti-corruption interventions, Blockchain in healthcare, Global health equity, Governance reform, Healthcare fraud, Medical corruption.

DOI: 10.53894/ijirss.v8i2.5397

Funding: This study received no specific financial support.

History: Received: 27 January 2025 / Revised: 28 February 2025 / Accepted: 5 March 2025 / Published: 14 March 2025

Copyright: © 2025 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Competing Interests: The authors declare that they have no competing interests.

Authors' Contributions: All authors contributed equally to the conception and design of the study. All authors have read and agreed to the published version of the manuscript.

Transparency: The authors confirm that the manuscript is an honest, accurate, and transparent account of the study; that no vital features of the study have been omitted; and that any discrepancies from the study as planned have been explained. This study followed all ethical practices during writing.

Publisher: Innovative Research Publishing

1. Introduction

Corruption in the health sector is a wide-ranging problem that inevitably affects medical systems worldwide. In particular, the pharmaceutical industry's involvement in corruption in medicine is highlighted. Medical corruption incorporates unethical and illegal bribery, fraud, and kickbacks; therefore, it is pervasive in healthcare provision, sales of pharmaceutical products, and regulatory bodies in the industry [1]. Medical corruption incorporates unethical and illegal acts of bribery, fraud, and kickbacks [2]. Medical corruption has far-reaching consequences beyond individual patients and localized health systems, thus affecting global health. It erodes confidence in healthcare systems globally by lowering public trust in healthcare professionals, institutions, and regulatory bodies. Once such corruption is institutionalized, it sets in motion a negative cycle where patients become suspicious of the motives behind their medical choices, leading to treatment delays, avoidance of care, and even public health crises. A classic case is the spread of fake or substandard drugs, which may have their genesis in corrupt practices in one country and then spread across borders, risking lives worldwide. Corruption also siphons vital resources from priority health services, aggravating health inequalities and hindering progress toward international goals, including the United Nations Agenda 2030 for Sustainable Development. As such, tackling medical corruption is a national concern and a global imperative to ensure equitable, transparent, and reliable healthcare for all people.

In this review, we can conclude that "medical corruption" denotes activities of health professionals, companies, regulatory agencies, or others working in the healthcare sphere that act contrary to ethical standards and legality, seeking to attain disproportionate financial or professional advantages. They may also apply to bribery, embezzlement, fraud, nepotism, and the manipulation of medical research or procurement procedures. These actors include healthcare professionals driven by fraudulent billing and overprescription of medication; pharmaceutical companies that work on kickbacks to prescribers and manipulate the results of clinical trials; and regulatory bodies shaped by capture with a failure to reinforce anti-corruption measures. We attempt to explain this in a framework based on an understanding underpinned by these different forms of corruption in medicine and its various health sector impacts by defining what arguably might be some medical corruption and its many associated activities and actors. This review is premised on an overview of the nature of corruption in medicine, defined by its scope, causes, and drivers, and an outline of strategies to combat such bribery. In this review, we argue that medical corruption represents a broad and greedy spectrum of unethical practices among various health stakeholders, significantly contributing to healthcare quality and equity depreciation. Based on a systematic analysis of its causes, consequences, and potential solutions, we attempted to provide an organized framework for understanding and dealing with medical corruption. Pharmaceutical corruption related to off-label drug promotion and price manipulation results in inappropriate prescriptions and inflated drug prices, adversely affecting patient health and healthcare costs [3-6]. The key to fighting corruption lies in a comprehensive approach that firmly engages medical services and pharmaceutical companies, secures transparency, accountability, and ethical conduct on all avenues, lets safety return to patients, controls expenses, and renews confidence in the public mind [7]. Medical corruption involves several unethical and illegal practices standard in the healthcare industry, including bribery, fraud, and manipulation of clinical trials. This review outlines corruption into three broad dimensions: (1) systemic causes, (2) corruption mechanisms, and (3) consequences. It also discusses potential interventions. We use a systematic approach to describe this complex phenomenon, focusing on particular forms of corruption and not viewing the phenomenon as a monolithic concept. As depicted in Figure 1, corruption in the healthcare sector typically stems from four primary sources: monetary motivations, inadequate regulations, moral quandaries, and insufficient supervision. These root causes give rise to corrupt activities such as kickbacks, dishonest invoicing, excessive prescription practices, and tampering with research data. The consequences of these unethical behaviors include inflated healthcare expenses, diminished patient confidence, compromised health outcomes, and heightened legal exposure for medical service providers.

Corruption in Healthcare: Causes, Processes, and Consequences




Figure 1.

The healthcare industry's corruption is rooted in four primary factors: monetary incentives, inadequate regulatory frameworks, ethical challenges, and insufficient oversight. These elements contribute to unethical practices such as payoffs, fraudulent invoicing, excessive drug payments, and manipulation of research results. The consequences of these dishonest activities include escalated healthcare expenses, diminished patient trust, unfavorable patient outcomes, and increased legal exposure for healthcare organizations.

1.1. Key Aspects of Medical Corruption

Medical corruption is a host of unethical acts aimed at destroying the integrity of health care. Pharmaceutical companies sometimes attract healthcare professionals to get them to prescribe specific medicines or devices. They do so through financial incentives, gifts, or kickbacks, compromising patient care and professional ethics [8].

Another facet is fraudulent practices: deceptive billing, insurance fraud, and research misconduct, all of which siphon resources from caring for bona fide patients, in addition to contributing to inflated healthcare costs. A significant factor is likely misleading promotion by pharmaceutical companies. This includes exaggeration of drug benefits, minimization of risks, and promotion of off-label use, which sometimes results in inappropriate prescriptions that harm patients [9, 10].

Regulatory capture is another crucial matter in which regulatory organizations and government agencies associated with health are captured by industry interests. This compromises their ability to ensure public health and safety. Patient exploitation is another explanation for medical corruption, where patients are subjected to unnecessary treatment for money-making purposes rather than for medical reasons. Apart from affecting patients' interests, this also leads to a waste of health resources [11].

Medical corruption requires consolidated efforts by healthcare professionals, policymakers, regulators, and the pharmaceutical industry. It defines the causes, consequences, and strategies to mitigate medical corruption, with extraction from academic sources in a manner that is astute and well-informed based on extensive research in the following sections [7].

1.2. Significance of the Issue

At the international level, the 2015 United Nations General Assembly's Agenda 2030 has warned of the dire necessity to fight corruption and bribery for a sustainable future [12, 13]. Corruption does not stay within geographical boundaries; much more so in healthcare, it assumes, apart from national and international dimensions, substantial global implications for development. Corruption does not remain within geographical boundaries; much more so in healthcare, it assumes a significant global impact on development [14].

1.2.1. Repercussions of Medical Corruption

Consequences of Medical Corruption: Far from victimless crimes, medical corruption has an echo effect throughout healthcare [15]. We must get to its roots by discussing its profound implications for various aspects of the healthcare ecosystem. A high-ranking impact in the healthcare sector is related to corruption in medicine, in which shocks are deeply reverberated in the system. It harms patients, increases costs and disparities, and jeopardizes public health. When personal economic gain is more important than clinical need, patients receive therapy that may be harmful and not required [16]. This is not a financial blow that prevents people from being involved. Health scheme members do so at exorbitant health costs through fraudulent billing, hiked drug prices, and ordering unnecessary tests, all heaped by these people. Ultimately borne by patients, insurers, and governments, such costs strain budgets and limit access to essential care [17, 18].

Table 1.

Summarizes the strengths, weaknesses, opportunities, and threats related to global efforts against medical corruption, including the status of current anti-corruption initiatives, challenges in health systems, technological advancements, and changing dimensions of the risks caused by medical corruption.

Strengths	Weaknesses
1. Increased awareness of medical corruption globally.	1. The complexity and multifaceted nature of medical corruption.
2. Existing anti-corruption initiatives and policies	2. Lack of comprehensive oversight and regulation.
3. Growing research and literature on the topic.	3. Insufficient transparency in healthcare systems.
4. International recognition (e.g., UN Agenda 2030)	4. Inadequate whistleblower protection
5. Ethical training programs for healthcare professionals.	5. Financial pressures on healthcare providers
6. Technological advancements for better monitoring.	6. Cultural normalization of corrupt practices
7. Increased public demand for transparency.	7. Complex pharmaceutical supply chains
8. Ethical guidelines and codes of conduct	8. Insufficient regulatory enforcement resources.
9. Growing emphasis on evidence-based medicine.	9. Ambiguous regulations on industry interactions
10. Interdisciplinary Approach to Combating Corruption	10. Profit-driven models compromising patient care.
Opportunities	Threats
1. Blockchain technology for transparent transactions.	1. Evolving sophisticated corruption methods.
2. AI and machine learning for fraud detection	2. Regulatory capture by industry interests
3. International anti-corruption collaboration	3. Economic pressures leading to corrupt practices.
4. Anti-corruption training in medical education.	4. Globalization Spreading Corrupt Practices
5. Strengthening legal frameworks	5. Political instability hampers efforts.
6. Public-private partnerships for integrity	6. Resistance to change from beneficiaries.
7. Empowerment of patient advocacy groups	7. Cybersecurity threats to data integrity
8. Standardized corruption risk assessment tools	8. Erosion of public trust in healthcare.
9. Increased funding for anti-corruption research.	9. Potential Retaliation Against Whistleblowers
10. Social media for transparency and accountability.	10. Increasing complexity of healthcare systems.

Medical corruption worsens health disparities by diverting resources to vulnerable populations. The most underserved communities, which need these resources the most, become disproportionately devastated if they are misused through corrupt practices, compounding already vast healthcare inequities [19, 20]. It can also facilitate the sale of substandard or false

medicines, which severely threaten public health. These are not only ineffective, harmful, unsafe, and useless medicines but also endanger patients' lives [21]. Such pressure puts healthcare professionals at an ethical crossroads, leading them to moral distress, burnout, and a decline in overall professional ethical standards [22]. Medical corruption jeopardizes patient well-being, increases costs, and erodes trust in the healthcare system, thus necessitating urgent attention to ensure ethical and sustainable healthcare globally [23]. This review comprehensively examines the types, causes, consequences, and mitigation strategies of medical corruption. The following SWOT analysis, shown in Table 1, provides more details about the possible areas of reform and vulnerabilities in fighting medical corruption.

This study offers unique insights and highlights the multifaceted nature of this issue. By examining causes such as inadequate oversight, financial incentives, ethical dilemmas, and cultural factors, this review adds depth to the analysis. It empowers stakeholders with knowledge in the fight against corruption, and concrete case studies deliver practical lessons for anyone concerned with healthcare integrity through transparency, accountability, and ethics.

1.3. Purpose of the Review

Medical corruption debases the fundamentals of healthcare and is based on various forms that bear ethical and legal dimensions. Only by understanding these types can clear insights be gained into the complexity of corruption in an industry [24]. Companies fuel pharmaceutical bribery by providing financial incentives, gifts, or kickbacks to health professionals for drug prescriptions. Such practices come at the cost of trust and integrity in the medical community for sheer monetary interests [25]. When dealing with healthcare providers related to upcoding or unbundling, such fraudulent activities lead to overbilling and rising healthcare costs, furthering insurance fraud. This hurts patients' wallets and poorly reflects the reputation of the healthcare system [26]. Off-label promotion is the marketing of drugs used by pharmaceutical companies for unapproved purposes, which endangers patient safety by avoiding scrutiny by public authorities. Here, patients are put at potential risk without having adequate safety and efficacy data, thus proving that 'more profit than ethics' is a mentality [27]. Corruption in the pharmaceutical industry has led to the development of substandard and counterfeit medications. These products lack any therapeutic effects or contain harmful substances, which pose a great dilemma for the patient. It is an unethical act in which lives are weighed against profit [28].

Research misconduct extends to corruption in research settings where fabricated data, manipulated results, or undisclosed conflicts of interest compromise scientific studies. This unethical behavior undermines the credibility of evidence-based medicine, hindering scientific progress and patient care [29-31]. Regulatory capture occurs when a regulatory agency becomes vulnerable to industrial influence, leading to the lax enforcement of standards and poor public health protection. This crisis has helped reduce public trust in regulatory bodies and raised questions about their interests [32, 33]. Unethical practices cast a shadow on health care, necessitating a comprehensive examination of their root causes, consequences, and strategies for combat. The battle against medical corruption is a legal and moral imperative, upholding fundamental healthcare ethics [34, 35].

Necessitated by this need for new frontier thinking in the fight against corruption in healthcare, we propose an "integrated multi-stakeholder anti-corruption model (IMACM)". This model espouses collaborative efforts between government entities, healthcare professionals, pharmaceuticals, civil society, and international organizations in the fight. The IMACM is founded on three principles envisaged to entrench transparency, accountability, and ethical practices along pharmaceutical value chains. IMACM identifies and pursues premium placement of the institution on e-platforms to trace pharmaceuticals' procurement and dispensation chains in real-time. Technology integration along the supply chain ensures transparency and forecloses the temptation for corrupt practices. Moreover, mandatory public disclosure of pharmaceutical prices and procurement contracts strengthens accountability as expenditures are open to stakeholder scrutiny for red flags of irregularity. The epicenter of IMACM lies in the issue of capacity and authority strengthening concerning regulatory authorities entrusted with the mandate to oversee the healthcare business sector. It seeks to enhance regulatory capacities, including types that could be used for enforcement to deal with anti-corruption measures, conflicts of interest, and unethical conduct committed by health professionals and pharmaceutical entities. This establishes a robust framework that expresses integrity and compliance with clearly stated and enforceable regulations. The call for ethics and anti-corruption training to be integrated into healthcare and pharmaceutical education is further deliberated upon hereunder by the IMACM. At an early stage of their career, this gives a person the start of developing an understanding of the risks associated with corruption. Hence, one is well equipped to navigate ethical dilemmas that may arise in health practice, leaving aside the induction of moral values.

Furthermore, types protecting whistleblowers must be instituted to ensure that individuals have the freedom to report corrupt activities without fear of reprisal, which acts as a check for transparency and accountability within the healthcare system. The IMACM is a practical way to combat corruption in health through collaborative engagement, regulatory enforcement, and ethical enablement. Operationalizing these principles will support stakeholders working toward a more open, accountable, and ethical pharmaceutical sector, in turn increasing public trust in authorities and enhancing the effectiveness of healthcare delivery.

These unethical practices ripple through the healthcare system and lead to significant consequences, as outlined below.

2. Types of Medical Corruption

2.1. Bribery And Kickback in Healthcare

Bribery and kickbacks in health care exemplify significant corruption, with pharmaceutical companies offering incentives to influence professionals' treatment decisions. This section explores the mechanics, implications, and factors that make health care professionals susceptible to unethical offers [36, 37].

2.2 The Mechanism of Pharmaceutical Bribery

Pharmaceutical bribery involves companies providing healthcare professionals with financial incentives, gifts, travel, or other perks. These incentives create a reciprocal relationship, expecting healthcare professionals to prescribe the company's products, sometimes at the expense of potentially more suitable treatment [38, 39]. Financial Incentives: These include direct payments, bonuses, and commissions tied to the volume of prescriptions for a specific drug. They have established substantial financial motivations for healthcare professionals [40]. Gifts and Hospitality: Pharmaceutical companies frequently indulge healthcare professionals in gifts, meals, and luxurious trips, subtly influencing them and fostering loyalty to the company's products [41, 42]. Sponsorship of Educational Events Companies sponsoring medical events and providing honoraria for speaking engagements can create ethical dilemmas for healthcare professionals. It might also instill a sense of indebtedness among sponsoring companies [41, 43]. Fraudulent billing practices, such as overcharging, upcoding, and ghosting patients, significantly contribute to healthcare cost inflation and undermine system integrity [44, 45]. Pharmaceutical bribery is unethical in healthcare and puts a profit on medical judgment to the detriment of patient care. The authors considered ethical and legal implications, consequences for health professionals, and strategies to combat such episodes [1]. The profound impact of pharmaceutical bribes requires serious thinking; it provokes one to delve into the thought-provoking features of the subject matter. Increased health costs: Overprescription of high-cost drugs after bribing greatly inflates health costs to patients and healthcare systems. This financial burden has prompted discussions on healthcare affordability, resource allocation, and the ethical implications of prioritizing profit over accessibility and affordability [46]. Pharmaceutical bribery raises intricate ethical questions at the core of health care. This demands an investigation into the delicate balance between patient welfare, trust, and financial interests in the medical field. Therefore, it is imperative to address these concerns so that healthcare remains ethical and patient-oriented rather than profit-driven [47].

2.3. Factors Making Healthcare Professionals Susceptible

Several factors make healthcare professionals more susceptible to pharmaceutical bribery.

Financial Pressures: Health professionals with educational debt, practice expenses, or unstable income may suffer financial pressure. Hence, it becomes a financial incentive for the pharmaceutical industry to entice the USD [47]. Lack of Transparency: The lack of sufficient transparency in the relationship between health professionals and pharmaceutical companies enables corrupt practices to occur [48]. Peer Pressure: Sometimes, health professionals respond to peer pressure from professionally affiliated groups and societies where it is customary to accept such incentives [49]. Bribery and kickbacks in pharmaceuticals compromise ethical health care. Subtle financial incentives may undermine patient care, distort prescriptions, and corrode trust. Dealing with these issues calls for comprehensive reforms and enhanced transparency by institutions and individuals in ethical medicine. The causes, consequences, and strategies for fighting corruption are discussed in the following sections of this paper. This discussion has been maintained in a tone that is as neutral as possible yet opinionated and includes relevant academic sources where appropriate [49].

2.4. Fraudulent Billing Practices

Fraudulent billing practices are techniques that healthcare providers use to maximize revenues, one of the key drivers of health cost inflation, and a sure way to undermine system integrity. Next, we review several practices: overcharging, upcoding, and ghost patients [50]. Overcharging: Artificially inflated costs of healthcare providers are characterized by higher billing than actual services or procedure expenses, increasing patient expenses, and augmenting the financial burden on insurers [51]. Upcoding: This is a fraudulent activity in which healthcare providers intentionally use higher billing codes for claims submitted to payers or insurance companies. It allows providers to overcharge care delivered using the code, representing a more extensive, complex, or costly service. Upcoding increases healthcare costs and can result in excessive testing or therapy [52]. Ghost patient creation: Several providers create "ghost patients" by inflating the number of patients seen or creating fictitious patients and submitting claims for services never provided, resulting in fraudulent claims and misallocating healthcare resources [53]. Phantom billing is when a healthcare provider presents a claim for services that are not rendered. In effect, this fraudulent act leads to undue payments and is against the legal and professional ethics of the professions [54].

2.5. Implications of Fraudulent Billing Practice

Financial Burden: Fraudulent billing is an unwarranted financial burden on patients, increasing healthcare costs for the latter through increased co-payments and deductibles. Moreover, this may provoke insurers to raise premiums, compounding the financial pressure on patients and the health system [55]. Resource Misallocation: Fraudulent billing burdens patients and has consequences for the misspending of healthcare funds, jeopardizing patient care. This happens whenever base ethical billing drains financial resources into unnecessary and unjustifiably large areas, extending to the underfunding of legitimate healthcare needs [56]. Legal Consequences: Fraudulent billing cases by healthcare providers face severe legal penalties such as hefty fines, license revocation, and imprisonment for serious breaches. These legal implications become deterrents and significantly serve to protect the ethical standards of billing [57]. Healthcare Access Impact: Fraudulent billing threatens healthcare accessibility in underserved communities. The resources flow towards fraudulent billing, causing overarching scarcity—the heaviest blow falls on the person of the marginalized group. These practices cause health inequities and raise ethical questions regarding fairness in allocating and treating resources [7].

2.6. Examples of Medical Suppliers' Influence on Healthcare Institutions

Medical suppliers' power over healthcare institutions is vast and has been demonstrated through several ethical and practical measures. The primary examples with the highest expression of power are as follows: Exclusive Agreements: Healthcare institutions bound to exclusive agreements with medical suppliers may fall under the radar of a probable monopoly, which would limit options in equipment and devices. This depends on whether one supplier can lead to losing quality and competitiveness [58]. Kickback and incentives. Such unethical practices in healthcare can include kickbacks, financial incentives, or lavish gifts by medical suppliers to institutional decision-makers. These inducements influence purchasing decisions, which jeopardize patients' financial gains [59]. Possible consequences of medical suppliers' influence: The influence of medical suppliers has several implications, and every one dramatically affects the healthcare landscape [60]. Increased Costs: Price hikes or the imposition of exclusive agreements on medical devices and equipment in health institutions can drastically increase costs. This extra burden can strain healthcare budgets and affect patients [61, 62]. Compromised Quality: overreliance on a single supplier, often influenced by corrupt practices, jeopardizes the quality of healthcare services and the safety of patients [63]. Erosion of trust: Exposure to unequal practice reduces trust between healthcare institutions, suppliers, and the public. This causes patients to lose faith in the health system, thus eroding confidence in medical services [64]. Resource Allocation Challenges: Chances of unethical influence in the relationship place the medical supplier–healthcare institution relationship at risk of overpricing in equipment, correspondingly diverting resources from critical needs in healthcare. Vigilance and ethical standards preserve the integrity of the healthcare system [65]. Financial incentives and ties Medical suppliers usually go amidst the chase for lucrative contracts with institutions in the health sector regarding the provision of devices and equipment. While such agreements could mutually benefit undergraduates, they are sometimes tinged by financial incentives and ties [66]. Kickbacks: Vendors can offer financial incentives or kickbacks to decision-makers at health institutions to gain favor or win contracts. This may create a conflict of interest and jeopardize proper decision-making [43]. Exclusive Contracts: Some medical suppliers advocate exclusive contracts and limit competition. This limits the choices of healthcare institutions and returns them to higher prices, which challenges quality as costs escalate [67].

2.7. Influence on Procurement Decisions

Importantly, medical suppliers have various strategies to influence purchasing decisions at health facilities. Lobbying and Advocacy: Suppliers advocate through lobbying, thus influencing institutional policies and procurement choices [67]. Freebies and Perks: Suppliers may give gifts, meals, or other perks to health professionals or ultimate decision-makers in institutions. In themselves, such acts can be innocuous, but they can engender a sense of reciprocal obligation and bias toward the supplier [68, 69]. Implications of Undue Influence: This means that the undue influence that medical suppliers can have on institutions in healthcare has enormous implications. Financial Impact: Healthcare institutions might pay a premium for devices and equipment, probably inflating budgets and diverting funds away from care [70]. Quality and Safety Concerns: Influence-driven decisions may mean that quality and safety issues are cast aside in the interest of money, thus affecting patient care and outcomes [71].

2.8. Addressing Undue Influence

The undue influence of medical suppliers must be balanced against the emphasis of healthcare institutions on transparency, ethical guidelines, and a competitive procurement environment. Policies relating to conflicts of interest, clear codes of conduct, and commitment to patients' best interests can help assuage these associated risks [72]. Vigilant monitoring is essential in the crucial relationship between healthcare institutions and medical suppliers to prevent undue influence, ensure ethical decision-making, and safeguard patient well-being. Subsequent sections will explore different aspects of medical corruption, maintaining a neutral yet opinionated tone and citing relevant academic sources where applicable [73].

3. Causes and Drivers of Medical Corruption

This section discusses the causes and drivers of medical corruption. We organized them along thematic lines, such as lack of supervision and regulation, financial incentives and pressures, profit-driven models in healthcare, ethical dilemmas, and cultural and social factors. This structured approach delineates the complexity of medical corruption and its underlying mechanisms.

One of the significant drivers of medical corruption is the presence of regulatory deficiencies, which create fertile grounds for corrupt practices to take root. These regulatory gaps manifest in several ways. Weak Enforcement: Regulatory healthcare agencies may struggle to enforce anti-corruption measures because of resource constraints, limited authority, or reluctance to robustly combat corruption. This can foster a permissive environment, allowing corrupt practices to go unchecked [7, 74, 75]. Ambiguity in Regulations: Unclear regulations allow corrupt actors to exploit legal loopholes. Ambiguous rules regarding interactions between healthcare professionals, pharmaceutical companies, and medical suppliers facilitate unethical practices without clear consequences [2]. Regulatory Capture: Regulatory agencies can experience regulatory capture, in which industry interests disproportionately influence decision-making. This control over oversight entities results in lax regulation, which fosters a corruption-prone environment [76].

Regulatory capture, in which industry interests disproportionately influence decision-making, fosters a corruption-prone environment. The strategies outlined below are designed to impact the core drivers of corruption.

3.1. Financial Incentives

Financial incentives in healthcare, essential for system sustainability and fair compensation, can paradoxically drive corruption. The pursuit of profits may prioritize monetary gains over patients' best interests [77]. This study examined the complex relationship between financial incentives and medical corruption.

3.2. Financial Pressures

Healthcare professionals and institutions burdened by educational debt and operational costs may face financial pressure. This challenging landscape can tempt individuals with the allure of financial gain through corrupt practices, acting as a catalyst for unethical behavior and compromising the integrity of healthcare services [78].

Regulatory failures create an enabling environment for medical corruption. Strengthening the regulatory framework through increased enforcement powers and clarifying guidelines can directly address this problem. For instance, giving any regulating body more teeth will increase its power to enforce penalties without loopholes to shield corrupt actors.

As discussed, financial pressure leads to many unethical actions among healthcare providers. Transparency measures in the form of public disclosure of healthcare costs and medical pricing dampen these pressures. This approach reduces the chances of fraud and keeps providers focused on patient outcomes rather than profit motives. They become victims because of cultural and social factors, such as the societal and medical professional normalization of corrupt practices. Building on this, medical education must include ethical training programs and enhance the types of protection for whistleblowers. This would ensure accountability at all levels, fostering a culture of transparency in health organizations.

3.3. Profit-Driven Healthcare

The risk of unethical behavior increases in healthcare systems that emphasize patient care. Shifting the focus from patient well-being to financial gain may overshadow the ethical considerations that guide healthcare practices. The pursuit of profits can lead to decisions that prioritize monetary incentives over patients' best interests [79].

3.4. Fee-for-Service Models

Fee-for-service models, which reward providers based on service volume, present several challenges. While intended for fair compensation, they can create perverse incentives, leading to overprescription and fraudulent billing. A focus on volume may compromise its quality [80]. Financial incentives in healthcare are a double-edged sword, crucial for system maintenance and fair compensation. In certain circumstances, they can drive corrupt practices. Balancing is vital for prioritizing patient well-being and ethical conduct within the financial framework of healthcare.

3.5. Ethical Dilemmas for Healthcare Providers

Healthcare professionals often face ethical dilemmas as they navigate the delicate balance between prioritizing patient well-being and managing financial incentives [81]. Accepting financial incentives, gifts, or perks from pharmaceutical companies or suppliers may create conflicts of interest, posing ethical challenges for healthcare providers in upholding patient-centered care amid financial enticements [43, 72]. In healthcare settings, professionals may face pressure to meet targets, leading to ethical challenges such as overprescribing medications or ordering unnecessary tests, as shown in Figure 2. This stems from the tension between financial demand and patient welfare [82].




Figure 2.

Examination of the cultural and socioeconomic factors influencing healthcare professionals, contributing to corruption in the healthcare system.

3.7. Cultural and Societal Factors

Cultural norms and societal attitudes can also contribute to corruption within the healthcare sector: corruption can become normalized in cultural or geographic contexts, influencing healthcare practices and complicating anti-corruption

efforts [83]. In societies without whistleblower protection, healthcare professionals who witness corruption may hesitate to report it because of fear of retaliation. The absence of protection acts as a deterrent to reporting and accountability [84]. Public attitudes significantly influence corruption in healthcare. Tolerance and ignorance diminish societal pressure for reform. Addressing this necessitates a comprehensive approach, reinforcing regulatory frameworks, addressing financial incentives, promoting ethical decision-making, and confronting cultural elements contributing to corruption [46]. The subsequent sections explore strategies for combating medical corruption, the potential consequences of inaction, and the roles of diverse stakeholders in fostering positive change, as shown in Figure 1. A neutral yet informed stance will be maintained, citing pertinent academic sources where applicable.

4. Consequences of Medical Corruption

Medical corruption has lasting effects on care systems, leading to far-reaching repercussions reverberating throughout every country's society. Unethical conduct undermines healthcare quality and affects the economy and the legal framework. Herein, we describe the consequences of corruption on patient care, economic stability, and the legal framework. We outline the separate but interrelated impacts that underline the necessity of implementing comprehensive anti-corruption efforts in health [85].

4.1. Impact on Patient Care

Corrupt practices misappropriate funds meant to finance facilities in terms of patient care, hence making them under-resourced. This consequently leads to the inability to deliver appropriate and timely care [16]. Medical corruption undermines healthcare quality because it licenses unqualified individuals through corrupt practices, such as giving or receiving bribes, as shown in Figure 3. Unskilled providers threaten patient safety, potentially resulting in poor health outcomes and not auguring confidence in the healthcare system [86]. Corruption of pharmaceutical procurement can cause essential medication shortages, leading to treatment delays and jeopardizing patients' lives. Patients in urgent need may suffer from the unavailability of crucial medications, resulting in avoidable suffering and loss [87]. Patient trust erodes when health outcomes are perceived as influenced by corruption rather than medical expertise. This erosion can lead to a reluctance to seek medical care, particularly in critical situations. Trust is fundamental to the patient-provider relationship, and its deterioration can profoundly impact healthcare utilization and outcomes [87, 88].

Figure 3 Impact of Corruption on Healthcare: The figure illustrates the four primary consequences of corruption in healthcare: compromised care quality, increased costs, diminished trust, and exacerbated health inequities, which significantly affect the quality, affordability, and equity of healthcare services.




Figure 3.

Impact of Corruption on Healthcare: The figure illustrates the four primary consequences of corruption in health care: compromised care quality, increased costs, diminished trust, and exacerbate health inequities, which significantly affect the quality, affordability, and equity of health care services.

4.2. Economic Consequences

Medical corruption, such as kickbacks and bribes, inflates healthcare costs, which are often passed on to patients. This increases expenses and burdens individuals and the government. Inflation strains national budgets and can potentially result in unequal access to care [89]. Corruption diverts healthcare resources for personal gain and obstructs infrastructure, research, and emergency preparedness. This misallocation hampers sector growth, impacts economic stability, and compromises vital investments in innovation and healthcare delivery [7, 75, 90].

4.3. Legal Ramifications

Engaging in corrupt practices, such as bribery or embezzlement of healthcare funds, may result in criminal charges. The severity of these charges varies, leading to fines, imprisonment, or a combination of these, depending on the gravity of the offense [91]. Healthcare professionals convicted of corruption may have their licenses revoked, thereby preventing them from practicing medicine. This serves as a deterrent and safeguard for patients against potentially harmful practices [92]. Depending on their involvement, institutions, hospitals, and pharmaceutical companies involved in corruption might be subjected to fines, suspension of license, or closure. Such penalties are instituted to ensure that institutions are answerable concerning malpractice. This multidimensional impact underlines the urgency to address and combat medical corruption through regulatory, ethical, and legal means [93].

4.4. International Consequences

Medical corruption has severe legal implications, especially when dealing with international pharmaceutical companies and cross-border transactions (Figure 4). This may call for cooperative investigations among countries and transnational law execution agencies to stop corruption across borders [7]. In conclusion, the severe consequences of medical corruption directly affect patient care and economic and legal standards. This factor justifies the need to address this issue to ensure equal and quality access to health and the credibility of the medical profession. This can be further explored more thoroughly through academic sources of research articles and government reports related to healthcare corruption [14].

Addressing Healthcare Challenges



Figure 4.

Schematic representation illustrating the healthcare challenges resulting from corruption, encompassing compromised patient care, increased healthcare costs, erosion of public trust, and exacerbation of health inequities.

Figure 4 Schematic representation illustrating the healthcare challenges resulting from corruption, encompassing compromised patient care, increased healthcare costs, erosion of public trust, and exacerbation of health inequities

5. Strategies for Combating Medical Corruptions

Medical corruption can be effectively addressed by implementing preventive measures at the local level, pursuing regulatory approaches, and collaborating internationally. This paper proposes various measures to reduce medical corruption, such as strengthening regulatory frameworks, increasing transparency and accountability, promoting ethical conduct, and building international collaboration, as shown in Figure 5. We provide examples of their implementation and underline the need for a multistakeholder approach. Several key strategies can effectively tackle this deeply entrenched problem [94-96].




Figure 5. Essential strategies for addressing medical corruption emphasize the significance of regulatory frameworks, transparency, ethics education, and whistleblower protection.

5.1. Transparency, Accountability, and Whistleblower Protection

Setting transparent standards for procurement procedures, financial transactions, and regulatory processes is one of the basic tenets of the fight against corruption. Transparency discourages corrupt practices by rendering them more challenging to conceal. It includes public information on healthcare expenses, medication pricing, and resource allocation to help identify irregularities and patterns of corruption [48]. Critical to the fight against medical corruption is making individuals and institutions accountable by investigating wrongdoings and determining their legal responsibility upon conviction. No tolerance should be shown for healthcare-related bribery, focusing on a clear investigation framework and legal actions [97, 98]. Whistleblowers are the key to exposing corruption in healthcare. Implementing robust safeguards is imperative to encourage individuals to come forward without fear of retaliation. This not only assists in uncovering corruption but also serves as a deterrent. Whistleblowers must be shielded from reprisals and legal protections [34, 84].

5.2. Promoting Ethical Behavior

Integrating ethics and anti-corruption education into medical curricula is crucial. This approach instills ethical values, emphasizing integrity, patient-centered care, and the severe consequences of corruption. Healthcare education should nurture ethical decision-making beyond clinical skills [89, 91]. Therefore, developing clear ethical guidelines for healthcare professionals and institutions is indispensable. These guidelines provide a framework for ethical decision-making that emphasizes patient welfare over personal gains. Ethical considerations should form the bedrock of healthcare practice [2, 22, 81]. Medical associations and licensing bodies must enforce professional codes of conduct rigorously. Violations should lead to disciplinary action, including license suspension or revocation. The healthcare community should self-regulate to maintain the highest ethical standards [24].

5.3. International Collaboration

Collaborative efforts between countries enhance investigative efficiency. International law enforcement cooperation allows the apprehension and prosecution of individuals involved in cross-border corruption. Joint investigations and extradition agreements deter those seeking to exploit jurisdictional variances [99]. Global anti-corruption contracts, such as the United Nations Convention against Corruption (UNCAC), offer a structured framework for countries to collaborate in combating corruption, including within the healthcare sector. Ratifying and diligently implementing such agreements are crucial for facilitating international cooperation and strengthening anti-corruption efforts [100]. Transparency discourages corrupt practices by rendering them more challenging to conceal. Rigorous drug safety and efficacy monitoring is essential to prevent corruption in the pharmaceutical industry [37].

5.4. Integrated Multi-Stakeholder Anti-Corruption Model (IMACM)

The Integrated Multi-Stakeholder Anti-Corruption Model emphasizes collaborative efforts from multiple stakeholders, including the government, healthcare professionals, pharmaceutical companies, civil society, and international organizations [101]. It is based on the following three broad principles.

Table 2.

Anti-Corruption Strategies in Health: This table comprehensively analyzes the diverse strategies employed to combat corruption in healthcare systems. The comparison is based on multiple criteria: efficacy, implementation challenges, adoption timelines, sustainability, financial implications, and global case studies. The strategies under examination encompass a broad spectrum, ranging from regulatory frameworks and transparency initiatives to patient advocacy and technological solutions, thereby providing a holistic perspective on the worldwide solutions to mitigate corruption within healthcare systems.

Strategy	Description	Effectiveness Rating	Challenges	Timeframe for Implementation	Sustainability	Financial Impact	Global Examples of Implementation
Regulatory Frameworks	Strengthening healthcare laws, policies, and standards	High	Complex international legal differences; regulatory loopholes	Long-term	High (with regular updates)	High Initial Costs	EU anti-corruption framework, WHO guidelines
Transparency Initiatives	Public disclosure of healthcare budgets, payments, and policies	Moderate	Limited access to comprehensive data; data privacy concerns	Medium-term	Moderate	Moderate	Open Payments in the US, UK's NHS transparency
Whistleblower Protection	Legal safeguards for individuals reporting corrupt practices	High	Fear of retaliation; insufficient legal protection in some regions	Long-term	High	Low	US False Claims Act, EU Whistleblower Protection Directive
Ethics and Compliance Training	Training healthcare professionals to adhere to ethical standards	Moderate	Varying adoption: continuous education needed for long-term impact	Short-term	Moderate	Moderate	Medical schools' ethics courses, Australia's anti-corruption training
Anti-Kickback Laws	Prohibition of financial incentives for patient referrals	High	Legal loopholes, weak enforcement in some regions	Long-term	High (with strong enforcement)	Moderate to High	US Stark Law, India's Anti-Kickback Laws
Patient Advocacy and Empowerment Programs	Programs to involve patients in identifying and reporting corruption	Moderate	Low patient awareness; resource constraints in low-income areas	Medium-term	Moderate	Low	NHS Patient Advocacy Services, South Africa's health ombudsman
Technological Solutions	Implementation of e-health records, blockchain for transactions	High	High costs of implementation, data security concerns	Long-term	High	High Initial Costs, Long-term Savings	Estonia's e-health system, Blockchain pilots in the UAE
Financial Audits and Monitoring	Regular audits to ensure financial accountability in healthcare	High	Resistance from stakeholders, lack of funding for regular audits	Medium-term	High	Moderate to High	Brazil's health budget audits, Nigeria's monitoring systems
Public-Private Partnerships	Collaborations to improve accountability and funding for healthcare transparency	Moderate	Conflicting interests between private and public sectors	Medium-term	Moderate	High	Gates Foundation health transparency projects, India's Ayushman Bharat

5.4.1. Transparency in Pharmaceutical Procurement and Pricing

Transparency is essential for preventing corruption and improving pharmaceutical procurement and pricing accountability. Establishing digital platforms that allow real-time tracking of pharmaceutical procurement and distribution chains will ensure the necessary transparency to facilitate the detection and prevention of corrupt activities. This would entail the public disclosure of all contracts related to the procurement prices of pharmaceuticals, thereby increasing accountability for all stakeholders and the public, who would closely monitor such transactions. This will strengthen trust and integrity in the pharmaceutical supply chain, ensuring that resources are used effectively for their intended purposes and ethical standards [102, 103].

5.4.2. Strengthening Regulatory Framework

Strengthening regulatory frameworks can help stem corruption in healthcare. The entrenchment of competent authorities and improvements in professional capacity would allow them to enforce top-to-bottom anticorruption measures without having any feeder loopholes for the actors to circumvent or go unpunished. This diffuses clear regulations concerning conflicts of interest and, thus, the unethical uses undertaken by health professionals and pharmaceutical firms. When strengthened, these frameworks can foster integrity and accountability cultures in the health sector and ensure that any financial incentives or wrongful practices will never jeopardize patient care [103-105].

5.4.3. Promoting Ethical Conduct and Whistleblower Protection.

Promoting good ethical conduct and protecting whistleblowers is essential for addressing the problem of medical corruption. Ethics and anti-corruption education should be integrated into the curriculum for health professionals early in their professional practice. Doctors, nurses, and pharmaceutical practitioners will work to understand the value of integrity and ethical practices from the beginning. In contrast, the availability of robust types of whistleblower protection will enable any individual who witnesses corrupt practices to report them without threats or intimidation. Subsequently, protecting and mainstreaming ethical conduct in health would endow the sector with the ability to safeguard patients and preserve trust and safety [106-108].

6. Case Studies: Illustrative Instances of Successful Anti-Corruption Initiatives

We provide representative best-practice cases of anti-corruption initiatives across various regions, each analyzed for strategy and results, as summarized in Table 2. Case studies yield practical insights that allow replicating successful models in healthcare settings that differ considerably.

6.1. Singapore's Healthcare System

Singapore is globally outstanding in anti-corruption; it boasts of its healthcare model and believes it is characterized by transparency and accountability. Strict enforcement of anti-corruption laws in healthcare, regular audits, and an effective reporting system have made a difference [109-111]. Any country that institutes zero tolerance with fair enforcement accompanied by preventive measures ensures that its anti-corruption strategy stands out among others. The Prevention of Corruption Act of 1960 reinstates the mandates under the PCA of the Corrupt Practice Investigation Bureau to define and extend coverage to corrupt practices [112]. The PCA ensures anti-corruption measures, establishes investigations regardless of rank or affiliation, and then lays down strict penalties—fines up to \$100,000, imprisonment for not more than five years, or both—for every corruption count. The CPIB forms Singapore's enforcement agency and is solely tasked with investigating offenses under the PCA [113, 114]. The following are some examples of anti-corruption practices in Singapore:

Singapore's healthcare system represents an anti-corruption model. It has consistently been ranked as one of the least corrupt countries in the world, entailing transparency and accountability. In addition, anti-corruption measures in the country include strict enforcement of laws, frequent audits in health care, and a robust internal reporting system. This underlines that success in Singapore means that stringent regulatory oversight and a cultural zero tolerance for corruption have contributed critically to healthcare [115, 116]. The overall proper goals of Singapore's e-government initiatives are reducing corruption in the public sector, increasing transparency and accountability in government transactions, and how technology could help deter corrupt practices. Technological progress has been instrumental in Singapore's efficient anti-corruption strategy [117].

Singapore's Whistleblower Protection Act protects individuals from corruption and offers protection against retaliation. This has gone quite a long way in exposing and dealing with corruption in all sectors, including the healthcare and public sectors [118]. Therefore, the ACW framework in Singapore is a fully integrated system that addresses corruption across sectors through integration with prevention strategies, detection, and punishment, emphasizing transparency and accountability, even in the private sector. This system adopts good corporate practices and business guidelines to provide a more effective way to prevent and deal with the risk of corruption [119]. These instances highlight Singapore's commitment to combating corruption through a potent mix of strict enforcement, technological advancements, and robust regulatory frameworks.

6.2. Hong Kong's Hospital Authority

The Healthcare Authority of Hong Kong, in taking a proactive approach to dealing with healthcare corruption, has clear strategies in place that include a staff code of conduct, professional guidelines, and a comprehensive program for continuing ethics education. The HA promotes the practice of whistleblowing and guarantees the anonymity of whistleblowers through solid measures. It emphasizes the need for clear conduct codes, continuous ethical formation, and safeguarding whistleblowing to maintain ethical standards concerning healthcare. The ICAC's anti-corruption guide for healthcare service

providers and the HA's initiatives to support the essential principles within this document identify a possible path toward acting on and upholding the principles of corruption minimization in healthcare. Highlights include that a doctor is being charged with fraud, which forms a basis for current activities to address corruption. Singapore's zero-tolerance culture, combined with technological solutions and robust regulatory frameworks, serves as a model for combating corruption [120].

Effective anti-corruption in health initiatives is very important in reducing its pervasiveness. The key strategies will involve the setting up of independent agencies for investigation, outlawing payments from pharmaceutical companies to health workers, creation of transparent health pricing, embarking on salary increases for workers, inclusion of anti-corruption views in reports on health expenditure processes, fostering multi-stakeholder engagements, and ensuring transparency, accountability, and mechanisms for whistleblowing. These combined efforts address corruption and ensure efficient, trustworthy, and integral health systems. It requires a holistic approach, establishing anti-corruption agencies, reinforced accountability, improved infrastructure, and a legal framework. Transparency measures include community monitoring, media campaigns, and publicizing performance metrics. Prevention involves higher worker salaries, resource allocation for better conditions, and incentives for ethical behavior. Multi-stakeholder involvement, transparent procurement, and whistleblowing are vital for effective anti-corruption initiatives, contributing to the integrity of healthcare systems [7, 121, 122].

6.3. Transparency International's "Medicines Transparency Alliance" (MeTA):

The Medicines Transparency Alliance (MeTA), globally active in countries such as the Philippines and Zambia, enhances pharmaceutical transparency. Advocating for the revelation of pricing and procurement data, MeTA reduces opportunities for corruption and promotes equitable pricing. Its successes exemplify the role of international collaboration and transparency in combating global medical corruption [123, 124]. These cases serve as examples for countries struggling with corruption and illustrate that robust regulation, ethical commitment, and proactive anti-corruption measures can have a significant positive impact. Innovative practices, such as MeTA, serve as examples by highlighting transparency and collaboration to mitigate the effects of corruption in healthcare regarding coverage and quality [124].

6.4. Key Takeaways

1. Vigilant regulatory oversight: Anti-corruption requires strong regulatory agencies to continuously oversee health and pharmaceutical entities. These agencies must have the power to impose heavy penalties and serve as strong deterrents for prospective offenders.
2. Education and training are crucial for healthcare professionals and staff. To foster a culture of integrity within the healthcare community, they should emphasize ethical principles in patient care and the severe consequences of corruption.
3. Whistleblower protection is essential to encourage people to report corruption without fear of retaliation. Indeed, in most cases, the early detection and prevention of corrupt practices will rely on whistleblowers' willingness and security.
4. It is vital to create a zero-tolerance culture for corruption in health care. This requires strong leadership and consistent enforcement of anti-corruption measures.
5. Anti-corruption initiatives in healthcare require sustained and consistent enforcement that recognizes the entrenched nature of corruption. To succeed, healthcare systems must pledge to ongoing and steadfast efforts over time.

Enduring Anti-Corruption Efforts: Successful initiatives in healthcare demand consistent and unwavering enforcement, recognizing that corruption can be deeply rooted. Healthcare systems must commit to persistent efforts over time [125, 126].

6.5. Applicability in Diverse Governance Contexts

While the case studies of Hong Kong and Singapore highlight successful anti-corruption efforts, challenges arise in applying such strategies to regions with weak governance. Therefore, we recommend the following.

6.5.1. Capacity Building

Capacity building is significant for the management of health interventions related to anticorruption. The supply of training and capacity-building interventions for local regulatory bodies and healthcare institutions gives them the will and the competence to effectively enforce anti-corruption policies and uphold ethical principles in their due course. Collaborative efforts with international bodies to provide technical assistance in anti-corruption initiatives add more weight through external expertise and experience. Large health systems and institutions can also resist corruption through comprehensive capacity-building strategies that ensure high-quality care [7, 127, 128].

6.5.2. Phased Implementation

To be effective and sustainable, anti-corruption measures should always be structured and incremental in the healthcare system. Staged adoption will mean that healthcare authorities can push ahead with limited pilot initiatives within target regions so that testing of their feasibility and impacts is implemented on a small scale before scaling it nationwide. This helps ensure a review based on feedback and outcomes from preliminary or pilot implementations for tailoring strategies to contexts and challenges. In a phased implementation, continuous review and improvement are core components that enable healthcare systems to enhance anti-corruption strategies in pursuit of maximal long-term impact iteratively [129].

6.5.3. Adaptability and Flexibility

The founding principles that should be considered when creating effective anti-corruption strategies in health systems are adaptability and flexibility. Instead, approaches should be designed to allow nature with diverse governance structures to react to various regional governance challenges [130, 131]. Tailoring anti-corruption measures to local needs might make them more relevant and effective for healthcare authorities. These solutions, which best fit the local stakeholders and align with a country's cultural and institutional norms, will be adopted in this space for local innovations within the larger framework of anti-corruption initiatives. Second, it will be owned and sustained, with interventions against corruption embedded into the very fiber of governance in health care so that transparency and accountability may be guaranteed over the long term [132-135].

7. Conclusion

This in-depth corruption in medicine now represents, through its key takeaways, some of its far-reaching consequences or costs in terms of the tattered patient trust base, spiraling healthcare expenses, and misallocation of critical resources. Legal implications, strategies against corruption, and practical case studies are in charge. A proper call to action is that supporting research, advocating for transparent anti-corruption policies, investing in ethical education, promoting international collaboration, and instilling a zero-tolerance culture in healthcare systems are critical. Addressing these drivers would lead to a healthcare environment conducive to transparency, accountability, and ethical conduct. In sum, fostering these frameworks of regulation and oversight for financial transparency and promoting ethical behavior strikes at the drivers of medical corruption discussed above. Addressing these drivers would lead to a healthcare environment conducive to transparency, accountability, and ethical conduct.

Medical corruption is seen as one of the significant barriers to affordable, quality health care. Strategies that make a targeted contribution to reducing this damaging impact are urgently needed because they understand the causes of corruption, whether regulatory failures or financial pressures. Such solutions will include increased regulatory capacity and extending whistleblower protection to help regain trust in health care.

References

- [1] S. Chattopadhyay, "Corruption in healthcare and medicine: Why should physicians and bioethicists care and what should they do?," *Indian J Med Ethics*, vol. 10, no. 3, pp. 153-9, Jul-Sep 2013. <https://doi.org/10.20529/ijme.2013.049>
- [2] G. J. Kontoghiorghes, "Ethics in medicines: Exposing unethical practices and corruption in all sectors of medicines is essential for improving global public health and saving patients' lives," *Medicines (Basel)*, vol. 8, no. 9, Sep 14 2021. <https://doi.org/10.3390/medicines8090054>
- [3] S. Batt, "Pharmaceutical company corruption and the moral crisis in medicine," *Hastings Cent Rep*, vol. 46, no. 4, pp. 10-3, Jul 2016. <https://doi.org/10.1002/hast.575>
- [4] M. A. Gagnon, "Corruption of pharmaceutical markets: Addressing the misalignment of financial incentives and public health," *J Law Med Ethics*, vol. 41, no. 3, pp. 571-80, Fall 2013. <https://doi.org/10.1111/jlme.12066>
- [5] S. Sismondo, "Epistemic corruption, the pharmaceutical industry, and the body of medical science," *Front Res Metr Anal*, vol. 6, p. 614013, 2021. <https://doi.org/10.3389/frma.2021.614013>
- [6] R. Khasawneh, M. Hailat, A. AlQudah, and A. H. Mohammad, "The dual impact of tax evasion, does tax evasion incentivize or dampen FDI, perspectives from the emerging economies of BRICS and CIVETS blocs?," *International Journal of Innovative Research and Scientific Studies*, vol. 8, no. 1, pp. 2796-2803, 2025.
- [7] E. H. Glynn, "Corruption in the health sector: A problem in need of a systems-thinking approach," *Front Public Health*, vol. 10, p. 910073, 2022. <https://doi.org/10.3389/fpubh.2022.910073>
- [8] D. W. Light, J. Lexchin, and J. J. Darrow, "Institutional corruption of pharmaceuticals and the myth of safe and effective drugs," *Journal of Law, Medicine & Ethics*, vol. 41, no. 3, pp. 590-600, 2013.
- [9] M. Sommersguter-Reichmann, C. Wild, A. Stepan, G. Reichmann, and A. Fried, "Individual and institutional corruption in European and US healthcare: Overview and link of various corruption typologies," *Applied Health Economics and Health Policy*, vol. 16, pp. 289-302, 2018.
- [10] T. K. Mackey et al., "The disease of corruption: Views on how to fight corruption to advance 21 st century global health goals," *BMC Medicine*, vol. 14, pp. 1-16, 2016.
- [11] M. Jofre-Bonet, J. Kamara, and A. Mesnard, "Corruption and informal sector households' participation in health insurance in Sierra Leone," *Plos One*, vol. 18, no. 4, p. e0281724, 2023.
- [12] R. Abdul Rahim, A. Mohd Amin, and N. T. Mohd Razali, "Scenario planning for development of a national anti-corruption framework," *Foresight*, vol. 23, no. 3, pp. 299-310, 2021. <https://doi.org/10.1108/fs-04-2020-0040>
- [13] V. Bozhenko, A. Boyko, and I. Voronenko, "Corruption as an obstacle of sustainable development," 2022: Springer, pp. 395-407.
- [14] P. J. García, "Corruption in global health: the open secret," *The Lancet*, vol. 394, no. 10214, pp. 2119-2124, 2019.
- [15] M. Petkov and D. Cohen, *Diagnosing corruption in healthcare*. Transparency International, 2016.
- [16] E. National Academies of Sciences and Medicine, "The critical health impacts of corruption," in crossing the global quality chasm: improving health care worldwide: National Academies Press (US), 2018.
- [17] S. Barlas, "Are hospital prices a bigger problem than drug prices?: Congress doesn't know, doesn't care," (in eng), *P t*, vol. 44, no. 5, pp. 259-299, May 2019.
- [18] E. Ortiz-Prado, J. S. Izquierdo-Condoy, and J. Vasconez-Gonzalez, "Corruption in Healthcare: Global Perspectives and the Recent Escalation of Violence in Ecuador's Public Medicine Procurement System," *Frontiers in Public Health*, vol. 11, p. 1259124.
- [19] W. J. Riley, "Health disparities: gaps in access, quality and affordability of medical care," (in eng), *Trans Am Clin Climatol Assoc*, vol. 123, pp. 167-72; discussion 172-4, 2012.
- [20] S. Artiga, K. Orgera, and O. Pham, "Disparities in health and health care: Five key questions and answers," *Kaiser Family Foundation*, 2020.

- [21] K. S. Ziavrou, S. Noguera, and V. A. Boumba, "Trends in counterfeit drugs and pharmaceuticals before and during COVID-19 pandemic," *Forensic Sci Int*, vol. 338, p. 111382, Sep 2022. <https://doi.org/10.1016/j.forsciint.2022.111382>
- [22] C. M. Farrell and B. J. Hayward, "Ethical dilemmas, moral distress, and the risk of moral injury: Experiences of residents and fellows during the covid-19 pandemic in the United States," *Acad Med*, vol. 97, no. 3s, pp. S55-s60, Mar 1 2022. <https://doi.org/10.1097/acm.0000000000004536>
- [23] G. A. Ogunbanjo and D. K. van Bogaert, "Ethics in health care: Healthcare fraud," *South African Family Practice*, vol. 56, no. 1, pp. S10-S13, 2014.
- [24] C. Ewuoso, S. Hall, and K. Dierickx, "How do healthcare professionals respond to ethical challenges regarding information management? A review of empirical studies," *Glob Bioeth*, vol. 32, no. 1, pp. 67-84, Apr 5 2021. <https://doi.org/10.1080/11287462.2021.1909820>
- [25] M. Khan *et al.*, "Incentivisation practices and their influence on physicians' prescriptions: A qualitative analysis of practice and policy in Pakistan," *PLOS Glob Public Health*, vol. 3, no. 6, p. e0001890, 2023. <https://doi.org/10.1371/journal.pgph.0001890>
- [26] A. Coustasse, W. Layton, L. Nelson, and V. Walker, "upcoding medicare: Is healthcare fraud and abuse increasing?," (in eng), *Perspect Health Inf Manag*, vol. 18, no. 4, p. 1f, Fall 2021.
- [27] G. A. Van Norman, "Off-label use vs off-label marketing: Part 2: Off-label marketing-consequences for patients, clinicians, and researchers," (in eng), *JACC Basic Transl Sci*, vol. 8, no. 3, pp. 359-370, Mar 2023. <https://doi.org/10.1016/j.jacbts.2022.12.012>
- [28] G. J. Buckley and L. O. Gostin, "Countering the problem of falsified and substandard drugs," 2013.
- [29] C. Design, "On being a scientist responsible conduct in research," 1995.
- [30] V. Lohsiriwat and S. Lohsiriwat, "Fraud and deceit in published medical research," *Journal-Medical Association of Thailand*, vol. 90, no. 10, p. 2238, 2007.
- [31] U. Jaffer and A. E. P. Cameron, "Deceit and fraud in medical research," *International Journal of Surgery*, vol. 4, no. 2, pp. 122-126, 2006.
- [32] F. Boehm, "Regulatory capture revisited—lessons from economics of corruption," *Internet Centre for Corruption Research (ICGG) Working Paper*, vol. 22, 2007.
- [33] B. Martin and R. Whitley, "A case of regulatory capture?," *Reconfiguring knowledge production: Changing authority relationships in the sciences and their consequences for intellectual innovation*, vol. 51, 2010.
- [34] K. Kenny, *Whistleblowing: Toward a new theory*. Harvard University Press, 2019.
- [35] J. C. Kohler, M. G. Martinez, M. Petkov, and J. Sale, "Corruption in the pharmaceutical sector: Diagnosing the challenges," 2016.
- [36] K. Hussmann, "Health sector corruption," *Practical recommendations for donors. CHR. Michelsen Institute. U4*, no. 2020, p. 10, 2020.
- [37] J. Lexchin, J. C. Kohler, M. A. Gagnon, J. Crombie, P. Thacker, and A. Shnier, "Combating corruption in the pharmaceutical arena," *Indian Journal of Medical Ethics*, vol. 3, no. 3, pp. 234-239, 2018.
- [38] M. G. Martinez, J. C. Kohler, and H. McAlister, "Corruption in the pharmaceutical sector," in *The Handbook of Business and Corruption: Cross-Sectoral Experiences*: Emerald Publishing Limited, 2017, pp. 329-361.
- [39] D. Peltier-Rivest, "The prevention and detection of corruption in pharmaceutical companies," *Pharmaceuticals Policy and Law*, vol. 19, no. 1-2, pp. 17-31, 2017.
- [40] K. Diaconu, J. Falconer, A. Verbel, A. Fretheim, and S. Witter, "Paying for performance to improve the delivery of health interventions in low- and middle-income countries," (in eng), *Cochrane Database Syst Rev*, vol. 5, no. 5, p. Cd007899, May 5 2021. <https://doi.org/10.1002/14651858.CD007899.pub3>
- [41] M.-M. Chren, C. S. Landefeld, and T. H. Murray, "Doctors, drug companies, and gifts," *Jama*, vol. 262, no. 24, pp. 3448-3451, 1989.
- [42] G. Marmat, P. Jain, and P. N. Mishra, "Understanding ethical/unethical behavior in pharmaceutical companies: A literature review," *International Journal of Pharmaceutical and Healthcare Marketing*, vol. 14, no. 3, pp. 367-394, 2020.
- [43] B. Lo and M. J. Field, "Conflicts of interest and medical practice," in *Conflict of interest in medical research, education, and practice*: National Academies Press (US), 2009.
- [44] J. M. Westfall, J. McCabe, and R. A. Nicholas, "Drug samples: Benefit or bait?—reply," *JAMA*, vol. 279, no. 21, pp. 1698-1699, 1998.
- [45] R. F. Adair and L. R. Holmgren, "Do drug samples influence resident prescribing behavior? A randomized trial," *The American Journal of Medicine*, vol. 118, no. 8, pp. 881-884, 2005. <https://doi.org/10.1016/j.amjmed.2005.02.031>
- [46] T. Bruckner, "The ignored pandemic: How corruption in healthcare service delivery threatens universal health coverage," 2019.
- [47] Y. K. Dwivedi *et al.*, "Opinion paper: "So what if ChatGPT wrote it?" Multidisciplinary perspectives on opportunities, challenges and implications of generative conversational AI for research, practice and policy," *International Journal of Information Management*, vol. 71, p. 102642, 2023/08/01/ 2023. <https://doi.org/10.1016/j.ijinfomgt.2023.102642>
- [48] A. Esfandiari, V. Yazdi-Feyzabadi, L. Zarei, A. Rashidian, and H. Salari, "Transparency in public pharmaceutical sector: The key informants' perceptions from a developing country," *BMC Health Services Research*, vol. 21, no. 1, p. 1316, 2021/12/07 2021. <https://doi.org/10.1186/s12913-021-07319-x>
- [49] R. S. Keyser, R. S. Sawhney, and L. Marella, "A management framework for understanding change in a lean environment," *Tékhné*, vol. 14, no. 1, pp. 31-44, 2016.
- [50] R. Flasher and M. A. Lamboy-Ruiz, "Impact of enforcement on healthcare billing fraud: Evidence from the USA," *Journal of Business Ethics*, vol. 157, pp. 217-229, 2019.
- [51] E. National Academies of Sciences and Medicine, "Crossing the global quality chasm: improving health care worldwide," 2018.
- [52] J. C. Robinson, "Theory and practice in the design of physician payment incentives," *The Milbank Quarterly*, vol. 79, no. 2, pp. 149-177, 2001.
- [53] J. Crombie, "Medical ghost-and guest-writing as corrupt practices and how to prevent them," *Integrity, Transparency and Corruption in Healthcare & Research on Health, Volume I*, pp. 141-158, 2020.
- [54] T. L. Leap, *Phantom billing, fake prescriptions, and the high cost of medicine: Health care fraud and what to do about it*. Cornell University Press, 2011.
- [55] N. Kumaraswamy, M. K. Markey, T. Ekin, J. C. Barner, and K. Rascati, "Healthcare fraud data mining methods: A look back and look ahead," (in eng), *Perspect Health Inf Manag*, vol. 19, no. 1, p. 1i, Winter 2022.
- [56] A. T. Ford *et al.*, "Understanding and avoiding misplaced efforts in conservation," *Facets*, vol. 6, no. 1, pp. 252-271, 2021.

- [57] D. A. Daccord and R. Irving, "Pitfalls in healthcare mergers and acquisitions-emerging issues," *Health Law.*, vol. 25, p. 42, 2012.
- [58] K. L. Gudiksen, A. D. Montague, J. S. King, A. Y. Gu, B. Fulton, and T. L. Greaney, "Preventing anticompetitive contracting practices in healthcare markets," 2020.
- [59] C. Cobanoglu and N. Cobanoglu, "The effect of incentives in web surveys: Application and ethical considerations," *International Journal of Market Research*, vol. 45, no. 4, pp. 1-13, 2003.
- [60] C. Shore, L. Brown, W. J. Hopp, E. National Academies of Sciences, and Medicine, "Causes and Consequences of Medical Product Supply Chain Failures," in *Building Resilience into the Nation's Medical Product Supply Chains: National Academies Press (US)*, 2022.
- [61] P. Kesavan and C. J. Dy, "Impact of health care reform on technology and innovation," *Hand Clin*, vol. 36, no. 2, pp. 255-262, May 2020. <https://doi.org/10.1016/j.hcl.2020.01.008>
- [62] T. Bodenheimer, "High and rising health care costs. Part 1: seeking an explanation," *Annals of internal medicine*, vol. 142, no. 10, pp. 847-854, 2005.
- [63] T. E. MacGillivray, "Advancing the culture of patient safety and quality improvement," *Methodist Debaquey Cardiovasc J*, vol. 16, no. 3, pp. 192-198, Jul-Sep 2020. <https://doi.org/10.14797/mdcj-16-3-192>
- [64] C. P. Smith, "First, do no harm: Institutional betrayal and trust in health care organizations," *J Multidiscip Healthc*, vol. 10, pp. 133-144, 2017. <https://doi.org/10.2147/jmdh.S125885>
- [65] A. Rawlings, L. Brandt, A. Ferreres, H. Asbun, and P. Shadduck, "Ethical considerations for allocation of scarce resources and alterations in surgical care during a pandemic," *Surg Endosc*, vol. 35, no. 5, pp. 2217-2222, May 2021. <https://doi.org/10.1007/s00464-020-07629-x>
- [66] L. V. L. Van Leeuwen, R. Mesman, H. Berden, and P. P. T. Jeurissen, "Reimbursement of care does not equal the distribution of hospital resources: An explorative case study on a missing link among Dutch hospitals," *BMC Health Serv Res*, vol. 23, no. 1, p. 1007, Sep 19 2023. <https://doi.org/10.1186/s12913-023-09649-4>
- [67] T. J. Hoerger and A. Meadow, "Developing medicare competitive bidding: A study of clinical laboratories," *Health Care Financ Rev*, vol. 19, no. 1, pp. 59-86, Fall 1997.
- [68] A. D. So, "Free gifts: Redundancy or conundrum?," *J Gen Intern Med*, vol. 13, no. 3, pp. 213-5, Mar 1998. <https://doi.org/10.1046/j.1525-1497.1998.00058.x>
- [69] A. G. Parsons, "Brand choice in gift-giving: Recipient influence," *Journal of Product & Brand Management*, vol. 11, no. 4, pp. 237-249, 2002.
- [70] M. Carr, V. Reddy, J. M. Anderson, M. Weaver, M. Hartwell, and M. Vassar, "Evaluating the relationship between industry sponsorship and conflicts of interest among systematic review authors on treatments for cannabis use disorder," *Substance Abuse*, vol. 43, no. 1, pp. 1180-1189, 2022. <https://doi.org/10.1080/08897077.2022.2074598>
- [71] D. D. Akinleye, L. A. McNutt, V. Lazariu, and C. C. McLaughlin, "Correlation between hospital finances and quality and safety of patient care," *PLoS One*, vol. 14, no. 8, p. e0219124, 2019. <https://doi.org/10.1371/journal.pone.0219124>
- [72] Q. Grundy et al., "Disclosure, transparency, and accountability: A qualitative survey of public sector pharmaceutical committee conflict of interest policies in the world health organization South-East Asia region," *Global Health*, vol. 18, no. 1, p. 33, Mar 18 2022. <https://doi.org/10.1186/s12992-022-00822-8>
- [73] F. Al-Shargie, U. Tariq, H. Mir, H. Alawar, F. Babiloni, and H. Al-Nashash, "Vigilance decrement and enhancement techniques: A review," *Brain Sci*, vol. 9, no. 8, Jul 26 2019. <https://doi.org/10.3390/brainsci9080178>
- [74] J. C. Kohler, "Fighting corruption in the health sector: Methods, tools and good practices," 2011.
- [75] T. Vian, "Review of corruption in the health sector: Theory, methods and interventions," *Health Policy and Planning*, vol. 23, no. 2, pp. 83-94, 2008.
- [76] B. M. Mitnick, "Capturing 'capture': Definition and mechanisms," *Handbook on the Politics of Regulation*, vol. 1, pp. 34-49, 2011.
- [77] A. Abduljawad and A. F. Al-Assaf, "Incentives for better performance in health care," *Sultan Qaboos Univ Med J*, vol. 11, no. 2, pp. 201-6, May 2011.
- [78] J. Gardner and B. Olden, "Cash management and debt management: Two sides of the same coin?," *Public Financial Management and Its Emerging Architecture*, pp. 283-310, 2013.
- [79] J. H. Krause, "Skilling and the pursuit of healthcare fraud," *U. Miami L. Rev.*, vol. 66, p. 363, 2011.
- [80] T. W. Feeley and N. S. Mohta, "New marketplace survey: transitioning payment models: Fee-for-service to value-based care," *NEJM Catalyst*, vol. 4, no. 6, 2018.
- [81] A. D. Graber, A. Bhandary, and M. Rizzo, "Ethical practice under accountable care," *HEC Forum*, vol. 28, no. 2, pp. 115-28, Jun 2016. <https://doi.org/10.1007/s10730-015-9280-x>
- [82] M. Davari, E. Khorasani, and B. M. Tigabu, "Factors influencing prescribing decisions of physicians: A review," (in eng), *Ethiop J Health Sci*, vol. 28, no. 6, pp. 795-804, Nov 2018. <https://doi.org/10.4314/ejhs.v28i6.15>
- [83] K. D. Martin, J. L. Johnson, and J. B. Cullen, "Organizational change, normative control deinstitutionalization, and corruption," *Business Ethics Quarterly*, vol. 19, no. 1, pp. 105-130, 2009.
- [84] D. Schultz and K. Harutyunyan, "Combating corruption: The development of whistleblowing laws in the United States, Europe, and Armenia," *International Comparative Jurisprudence*, vol. 1, no. 2, pp. 87-97, 2015.
- [85] E. Ortiz-Prado, J. S. Izquierdo-Condo, and J. Vasconez-Gonzalez, "Corruption in healthcare: Global perspectives and the recent escalation of violence in Ecuador's public medicine procurement system," (in eng), *Front Public Health*, vol. 11, p. 1259124, 2023. 10.3389/fpubh.2023.1259124
- [86] S. Chattopadhyay, "Corruption in healthcare and medicine: Why should physicians and bioethicists care and what should they do," *Indian J Med Ethics*, vol. 10, no. 3, pp. 153-9, 2013.
- [87] J. C. Kohler and T. Wright, "The urgent need for transparent and accountable procurement of medicine and medical supplies in times of covid-19 pandemic," *J Pharm Policy Pract*, vol. 13, p. 58, 2020. <https://doi.org/10.1186/s40545-020-00256-w>
- [88] D. Musa, R. Schulz, R. Harris, M. Silverman, and S. B. Thomas, "Trust in the health care system and the use of preventive health services by older black and white adults," (in eng), *Am J Public Health*, vol. 99, no. 7, pp. 1293-9, Jul 2009. <https://doi.org/10.2105/ajph.2007.123927>
- [89] S. Gupta, H. Davoodi, and E. Tiongson, "Corruption and the provision of health care and education services," in *The political economy of corruption: Routledge*, 2001, pp. 123-153.

- [90] U. Myint, "Corruption: Causes, consequences and cures," *Asia Pacific Development Journal*, vol. 7, no. 2, pp. 33-58, 2000.
- [91] A. Fajar and C. Muriman, "Prevention of Corruption through Anti-Corruption Education," 2018: Atlantis Press, pp. 646-649.
- [92] C. G. Roy, "Patient safety functions of state medical boards in the United States," *Yale J Biol Med*, vol. 94, no. 1, pp. 165-173, Mar 2021.
- [93] W. P. Olsen, "The anti-corruption handbook," *How to Protect Your Business in the Global Marketplace*, vol. 172, pp. 1-193, 2010.
- [94] E. H. Glynn, "Corruption in the health sector: A problem in need of a systems-thinking approach," *Frontiers in Public Health*, vol. 10, p. 910073, 2022.
- [95] J. Munywoki *et al.*, "How does corruption influence health system efficiency? A case study of two counties in Kenya," *MedRxiv*, pp. 2023-06, 2023.
- [96] G. Saeed and J. C. Kohler, "Corruption in Healthcare Procurement," in *Routledge Handbook of Public Procurement Corruption*: Routledge, pp. 94-112.
- [97] S. N. M. Young, "Why civil actions against corruption?," *Journal of Financial Crime*, vol. 16, no. 2, pp. 144-159, 2009.
- [98] Z. Chang, V. Rusu, and J. C. Kohler, "The global fund: Why anti-corruption, transparency and accountability matter," *Globalization and Health*, vol. 17, no. 1, pp. 1-11, 2021.
- [99] M. Pieth, "International cooperation to combat corruption," *Corruption and the Global Economy*, pp. 119-131, 1997.
- [100] A. Argandoña, "The United Nations convention against corruption and its impact on international companies," *Journal of Business Ethics*, vol. 74, pp. 481-496, 2007. <https://doi.org/10.1007/s10551-007-9524-z>
- [101] M. Md. Abdul Kaium and J. D. Kim, "International Resistance Networks for Anti-corruption: Multi-stakeholder Mechanisms," in *Peace, Justice and Strong Institutions*, W. Leal Filho, A. M. Azul, L. Brandli, P. G. Özuyar, and T. Wall Eds. Cham: Springer International Publishing, 2019, pp. 1-14.
- [102] H. K. Sama, "Transparency in competitive tendering: The dominance of bounded rationality," *Cogent Business & Management*, vol. 9, no. 1, p. 2147048, 2022/12/31 2022. <https://doi.org/10.1080/23311975.2022.2147048>
- [103] I. Adam, "Transparency, accountability, and integrity of public procurement systems."
- [104] M. Gholami, A. Takian, M. J. Kabir, A. Olyaeemanesh, and M. Mohammadi, "Transparency interventions to improve health system outcomes in low and middle-income countries: A narrative systematic review," *BMJ Open*, vol. 14, no. 6, p. e081152, 2024.
- [105] L. Johnson, "Effectiveness of anti-corruption laws in developing countries," *International Journal of Law and Policy*, vol. 9, no. 2, pp. 1-14, 2024.
- [106] G. Onyango, "Whistleblower protection in developing countries: A review of challenges and prospects," *SN Business & Economics*, vol. 1, no. 12, p. 169, 2021/11/24 2021. <https://doi.org/10.1007/s43546-021-00169-z>
- [107] P. Kagiass, A. Garefalakis, I. Passas, P. Kyriakogkonas, and N. Sariannidis, "Whistleblowing based on the three lines model," *Administrative Sciences*, vol. 14, no. 5, p. 83, 2024.
- [108] A. Al Qudah and M. A. Hailat, "Deciphering the links: Evaluating central bank transparency impact on corruption perception index in G20 countries," *Journal of Money Laundering Control*, vol. 28, no. 1, pp. 1-14, 2025. <https://doi.org/10.1108/jmlc-01-2024-0016>
- [109] J. S. T. Quah, "Curbing corruption in Singapore: the importance of political will, expertise, enforcement, and context," in *Different Paths to Curbing Corruption*: Emerald Group Publishing Limited, 2013, pp. 137-166.
- [110] G. Silverstein, "Singapore: the exception that proves rules matter," *Rule by law: The politics of courts in authoritarian regimes*, pp. 73-101, 2008.
- [111] S. Choon-Yin, "Singapore's experience in curbing corruption and the growth of the underground economy," *Sojourn: Journal of Social Issues in Southeast Asia*, vol. 20, no. 1, pp. 39-66, 2005.
- [112] W. Yu, *Anti-corruption strategies in singapore: Demystifying the singapore model*. CRC Press London and New York, 2015.
- [113] C. P. I. Bureau. "Singapore's Corruption Control Framework." <https://www.cpib.gov.sg/about-corruption/prevention-and-corruption/singapores-corruption-control-framework/> (accessed 13/12/2023, 2023).
- [114] Y. L. Seng and A. Martin, "Anti-Corruption in Singapore," *Global compliance news*.
- [115] N. Zúñiga, *Anti-corruption in the health sector in Southeast Asia*. JSTOR, 2018.
- [116] N. Zuniga, "Anti-corruption in the health sector in Southeast Asia-U4 anti-corruption helpdesk," 2019.
- [117] C. Castro and I. C. Lopes, "E-government as a tool in controlling corruption," *International Journal of Public Administration*, vol. 46, no. 16, pp. 1137-1150, 2023.
- [118] S. L. Advice. "Laws Protecting Informers/Whistleblowers in Singapore." <https://singaporelegaladvice.com/law-articles/laws-protecting-informers-whistleblowers-singapore/> (accessed 13/12/2023, 2023).
- [119] K. T. Hin, "Corruption control in Singapore," *Tokyo: United Nations Asia and Far East Institute for the Prevention of Crimes and the Treatment of Offenders*, 2013.
- [120] ICAC. "Integrity in Practice online Guide for Medical Professionals " <https://hkbedc.icac.hk/medicalguide/public/issue-acceptance.html> (accessed 19/12/2023, 2023).
- [121] R. Gaitonde, A. D. Oxman, P. O. Okebukola, and G. Rada, "Interventions to reduce corruption in the health sector," *Cochrane Database Syst Rev*, vol. 2016, no. 8, p. Cd008856, Aug 16 2016. <https://doi.org/10.1002/14651858.CD008856.pub2>
- [122] N. Naher, R. Hoque, M. S. Hassan, D. Balabanova, A. M. Adams, and S. M. Ahmed, "The influence of corruption and governance in the delivery of frontline health care services in the public sector: A scoping review of current and future prospects in low and middle-income countries of south and south-east Asia," *BMC Public Health*, vol. 20, pp. 1-16, 2020.
- [123] G. Stedman-Bryce, F. Schatz, C. Hodgkin, and P. Balogun, "Medicines Transparency Alliance (MeTA) Evaluation," *e-Pact. Available at: www.itad.com/wpcontent/uploads/2016/05/MeTA-Evaluation-Final-Report.pdf*, 2015.
- [124] O. World Health, "Medicines transparency alliance (MeTA): pathways to transparency, accountability an access: Cross-case analysis and review of phase II," 2016.
- [125] J. T. Baines, C. N. Taylor, and F. Vanclay, "Ethical issues and dilemmas," *New Directions in Social Impact Assessment: Conceptual and Methodological Advances*. Cheltenham: Edward Elgar, pp. 96-113, 2011.
- [126] M. D. Havens, "Learning from ethical dilemmas," *Journal of Experiential Education*, vol. 10, no. 1, pp. 12-15, 1987.

- [127] K. DeCorby-Watson, G. Mensah, K. Bergeron, S. Abdi, B. Rempel, and H. Manson, "Effectiveness of capacity building interventions relevant to public health practice: A systematic review," *BMC Public Health*, vol. 18, no. 1, p. 684, 2018/06/01 2018. <https://doi.org/10.1186/s12889-018-5591-6>
- [128] J. C. Kohler and A. Bowra, "Exploring anti-corruption, transparency, and accountability in the world health organization, the united nations development programme, the world bank group, and the global fund to fight AIDS, Tuberculosis and Malaria," *Globalization and Health*, vol. 16, no. 1, p. 101, 2020/10/20 2020. <https://doi.org/10.1186/s12992-020-00629-5>
- [129] J. Lehtinen, G. Locatelli, T. Sainati, K. Artto, and B. Evans, "The grand challenge: Effective anti-corruption measures in projects," *International Journal of Project Management*, vol. 40, no. 4, pp. 347-361, 2022/05/01/ 2022. <https://doi.org/https://doi.org/10.1016/j.ijproman.2022.04.003>
- [130] A. Azamov, "The role of the united nations anti-corruption convention in the fight against corruption," *Евразийский журнал академических исследований*, vol. 4, no. 6, pp. 219-223, 2024.
- [131] N. Kuanishbaeva, "The international legal foundations of anti-corruption efforts," *Центральноазиатский журнал академических исследований*, vol. 2, no. 5, pp. 18-24, 2024.
- [132] S. Rose-Ackerman, "The consensus on corruption," *Rethinking Corruption: Reasons Behind the Failure of Anti-Corruption Efforts*, p. 16, 2024.
- [133] J. Wolfensohn, "Fighting corruption, fighting for corruption," *Rethinking Corruption: Reasons Behind the Failure of Anti-Corruption Efforts*, p. 207, 2024.
- [134] G. Reçi, "The fight against corruption as a prerequisite for the country's integration into the European Union (EU)," *Editorial Board*, p. 74.
- [135] L. E. T. Feikema, "Anti-corruption law as a fiction: The illusion of serving morality by controlling it through rules and regulations with an international reach," *Global Perspectives*, vol. 5, no. 1, 2024.